Skip to search formSkip to main contentSkip to account menu

FP 21399

Known as: FP-21399 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ChlorobenzenesNaphthalenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Fluorine-18 labeled FP-21399 for lymph node PET imaging
Review
2004
Review
2004
New advances in HIV entry inhibitors development.
Considerable advances have been made in the last years in the design of derivatives acting as inhibitors of HIV entry and fusion… 
2001
2001
FP-21399 (Lexigen Pharmaceuticals).
Lexigen (formerly Fuji ImmunoPharmaceuticals) is developing FP-21399, a bis-azo compound, for the potential treatment of HIV… 
2000
2000
A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study.
FP-21399 is a bis(disulfonaphthalene) derivative that prevents human immunodeficiency virus (HIV) infection of uninfected cells… 
2000
2000
Liquid chromatographic determination of FP-21399 in plasma of patients with HIV infection.
1998
1998
Looking down the drug pipeline.
Reports at the 5th Conference on Retroviruses and Opportunistic Infections addressed new anti-HIV agents in primary phases of… 
1997
1997
FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes
The identification of fusin and other chemokine receptors as coreceptors for HIV-1 has renewed the interest in agents that may… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)